Charantin (Bitter Melon Steroidal Saponin · Antidiabetic · Insulin-mimetic · Karela)

Compound	Charantin
Chemical class	Terpenoid — Steroidal Saponin (Cucurbitane-type mixed steroid saponin; beta-sitosterol glucoside + stigmasterol glucoside mixture)
CAS	N/A — charantin is a mixture; primary components: sitosterol-glucoside + stigmasterol-glucoside
Primary source	Momordica charantia (bitter melon / bitter gourd / karela, fruit and seeds)
Key applications	Antidiabetic; insulin-mimetic; glucose uptake enhancement; hypoglycaemic
Claim strength	Moderate
Typical form	Bitter melon extract standardised to charantin content; karela powder; bitter melon juice
Buy from Herbuno	Bitter Gourd Powder - Momordica charantia | Karela → Momordica charantia (Bitter Melon) Extract Powder →

Name origin: From Momordica charantia (bitter melon species name; charantia possibly from Arabic or local South Asian naming). Charantin is not a single molecular entity but a mixture of two steroidal glycosides: β-sitosterol glucoside and stigmasterol glucoside, found specifically in bitter melon (Momordica charantia). This distinguishes charantin from the cucurbitane-type triterpene glycosides (momordicins, cucurbitacins) also present in bitter melon — charantin is specifically the steroidal saponin fraction responsible for bitter melon’s primary hypoglycaemic activity. Traditional use: Bitter melon (Momordica charantia, known as karela in Hindi, bitter gourd, or balsam pear) is used in Ayurvedic, traditional Chinese, and Latin American traditional medicine specifically for diabetes management — one of the oldest and most globally widespread botanical antidiabetic remedies. Karela is consumed as a vegetable in South Asian, Southeast Asian, and Caribbean diets. The consistency of traditional use for diabetes across multiple independent ethnomedicinal traditions is remarkable and has driven substantial pharmacological research. Research trajectory: Charantin-containing bitter melon extracts have been studied in multiple human RCTs for type 2 diabetes — with inconsistent results. Some trials show significant HbA1c and fasting glucose reduction; others show no effect. The inconsistency is attributed to: varying charantin content in preparations, mixed extract contributions from charantin + momordicins + polypeptide-p + vicine (another hypoglycaemic compound), and variable patient populations. Commercial source: Bitter Gourd/Karela extract from Herbuno in multiple forms.

---

Evidence for Charantin Applications

Antidiabetic — insulin-mimetic mechanism: Charantin (sitosterol glucoside fraction) activates GLUT4 translocation to the plasma membrane in muscle and adipose cells independently of insulin — an insulin-mimetic effect. It also activates AMPK, reduces hepatic glucose production, and has weak PPAR-γ agonism. The combined mechanisms address multiple aspects of type 2 diabetes pathophysiology. Claim strength: Moderate (mechanism established; clinical results inconsistent).

Clinical evidence summary: A systematic review (Ooi et al., 2012; BMC Complement Med; 4 RCTs) found limited evidence to recommend bitter melon for T2DM — two trials showed significant HbA1c reduction; two showed no effect. The heterogeneity of preparations used makes pooled analysis difficult. Despite this, bitter melon/charantin has high real-world usage in diabetic populations across South Asia, Southeast Asia, and the Caribbean. The 2022 NICE review on complementary treatments for T2DM assigned bitter melon a “promising” but not “proven” classification. Claim strength: Moderate (inconsistent clinical; mechanism established).

---

Frequently Asked Questions — Charantin

What is the difference between charantin, polypeptide-p, and momordicin in bitter melon?
Bitter melon contains multiple bioactive classes: (1) charantin — steroidal saponin mixture (beta-sitosterol + stigmasterol glucosides); (2) polypeptide-p (also called plant insulin or p-insulin) — a 166-amino acid polypeptide with structural similarity to bovine insulin, active when injected but degraded orally; (3) vicine — a pyrimidine glycoside with hypoglycaemic activity in G6PD-deficient individuals (caution in G6PD deficiency); (4) momordicin I & II — cucurbitane-type triterpenes with anti-inflammatory and antidiabetic activity. The totality of bitter melon’s antidiabetic effect is likely a combination of all these classes, which is why standardised extracts targeting only charantin may not replicate whole fruit efficacy.

Can bitter melon lower blood sugar too much?
Yes — hypoglycaemia is a documented risk with bitter melon consumption, particularly in: (1) patients already on antidiabetic medications (additive hypoglycaemic effect); (2) G6PD-deficient individuals (vicine in bitter melon can cause haemolytic anaemia and hypoglycaemia in this population); (3) diabetic patients in early treatment with a well-functioning pancreas (charantin’s insulin-mimetic activity adds to endogenous insulin). Standard advisory: bitter melon supplements should not be taken with antidiabetic medications without blood glucose monitoring and prescriber advice.

Is karela (bitter melon) effective as a food for diabetes management?
Regular consumption of bitter melon as a dietary vegetable is associated with modest glycaemic benefits in observational studies of South Asian diabetic populations — this represents the most ecologically valid evidence for bitter melon in diabetes management. The whole vegetable provides charantin + polypeptide-p + vicine + momordicin + dietary fibre (which independently reduces postprandial glucose) in natural ratios that may be more effective than isolated fractions. Traditional dietary use of karela in Indian and Southeast Asian diabetes management has millennia of empirical evidence supporting it at food doses that are inherently safer than concentrated extracts.

What is the best standardisation marker for bitter melon extract?
Commercial bitter melon extracts are standardised to various markers: (1) charantin content (most common; typically 1–10% charantin by HPLC); (2) total bitter principles (often reported as “charantin equivalents”); (3) momordicin content; (4) total saponin content. The lack of a single agreed standardisation marker for bitter melon reflects the multi-component antidiabetic mechanism. For consistency with clinical trial preparations, specify the charantin assay method (UV spectrophotometric or HPLC) and request lot-to-lot consistency certificates from Herbuno.

Related compounds: Momordicin, Cucurbitacin, Stigmasterol, Stevioside

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery